NN 9101
Alternative Names: NN9101Latest Information Update: 04 Feb 2010
Price :
$50 *
At a glance
- Originator Novo Nordisk
- Class
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 04 Feb 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in Denmark (unspecified route)
- 13 Jun 2006 Phase-I clinical trials in Type-2 diabetes mellitus in Denmark (unspecified route)